Characteristics | UEC | UCCC | USC | UMC | P | Pa | Pb | Pc |
---|---|---|---|---|---|---|---|---|
n | 396 | 34 | 106 | 34 | Â | Â | Â | Â |
Chemotherapy, n (%) |  |  |  |  |  < 0.001 | 0.052 |  < 0.001 |  < 0.001 |
 Yes | 165 (41.7%) | 20 (58.8%) | 81 (76.4%) | 27 (79.4%) |  |  |  |  |
 No | 231 (58.3%) | 14 (41.2%) | 25 (23.6%) | 7 (20.6%) |  |  |  |  |
Radiotherapy, n (%) |  |  |  |  |  < 0.001 |  < 0.001 |  < 0.001 |  < 0.001 |
 Yes | 36 (9.1%) | 11 (32.4%) | 43 (40.6%) | 10 (29.4%) |  |  |  |  |
 No | 360 (90.9%) | 23 (67.6%) | 63 (59.4%) | 24 (70.6%) |  |  |  |  |
OS, n (%) |  |  |  |  |  < 0.001 |  < 0.001 |  < 0.001 | 1.000 |
 Alive | 384 (97%) | 25 (73.5%) | 81 (76.4%) | 33 (97.1%) |  |  |  |  |
 Dead | 12 (3%) | 9 (26.5%) | 25 (23.6%) | 1 (2.9%) |  |  |  |  |
 OS-time(months), median (IQR) | 55.65 (46.42, 71.13) | 38.02 (27.36, 55.58) | 36.83 (25.48, 60.08) | 45.87 (34.88, 62.93) |  < 0.001 |  < 0.001 |  < 0.001 | 0.001 |
PFS, n (%) |  |  |  |  |  < 0.001 |  < 0.001 |  < 0.001 | 0.227 |
 Stable | 380 (96%) | 24 (70.6%) | 75 (70.8%) | 31 (91.2%) |  |  |  |  |
 Recurrent | 9 (2.3%) | 5 (14.7%) | 11 (10.4%) | 2 (5.9%) |  |  |  |  |
 Unknown | 7 (1.8%) | 5 (14.7%) | 20 (18.9%) | 1 (2.9%) |  |  |  |  |
PFS-time(months), median (IQR) | 55.90 (46.43, 71.13) | 41.10 (31.33, 56.53) | 40.93 (26.53, 62.53) | 45.67 (36.83, 62.97) |  < 0.001 |  < 0.001 |  < 0.001 |  < 0.001 |